Uni-Bio Science Group Receives NMPA Approval for 金因康® (Diquafosol Sodium Eye Drops), Advancing Dry Eye Syndrome Treatment in China
HONG KONG SAR - EQS Newswire - 21 May 2025 - Uni-Bio Science Group Limited (the 'Company', together with its subsidiaries, the 'Group') proudly announces that its new ophthalmology product, 金因康® (Diquafosol Sodium Eye Drops), has received marketing approval from the China National Medical Products Administration (NMPA) [Approval Number: 國藥准字H20254149]. This milestone strengthens the Group's portfolio in ophthalmology, addressing the growing demand for innovative treatments in China's dry eye syndrome market, which affects an estimated 360 million individuals.
As the Group's second ophthalmology drug following GeneSoft®, 金因康® addresses the underlying causes of dry eye syndrome by activating P2Y2 receptors to stimulate tear fluid and mucin secretion. It offers:
--> Improved tear layer normalization and corneal epithelial repair.
--> Treatment for patients with dry eye accompanied by abnormal tear-associated corneal epithelial defects.
--> A next-generation option for more effective and patient-friendly care.
China's dry eye syndrome market is projected to surpass RMB 42 billion by 2030, growing at a CAGR of 28.4%, driven by increased screen time and evolving lifestyles. 金因康® is well-positioned to capture this growing demand with its proven efficacy and safety, widely recognized since the originator launched in Japan in 2010.
To ensure rapid market penetration, the Group has expanded its sales force and integrated resources across hospitals, pharmacies, and e-commerce platforms. Strategic partnerships with API suppliers have secured high-quality raw materials at competitive costs, further enhancing 金因康®'s affordability and market competitiveness.
Looking ahead, Uni-Bio Science Group will continue to focus on clinical needs and invest in R&D to expand its ophthalmic drug pipeline. With over 20 years of technological expertise, the Group is committed to delivering high-quality medical solutions, raising the standards of ophthalmic care, and solidifying its leadership in China's growing ophthalmology market.
About Uni-Bio Science Group
Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and sales of pharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has three GMP manufacturing bases in Beijing, Dongguan and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology. Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.
About 金因康®
Diquafosol Sodium Eye Drops are a medication for treating dry eye disease and are suitable for patients diagnosed with dry eye accompanied by abnormal tear-associated corneal epithelial defects. Diquafosol Sodium represents the next generation of dry eye medication, offering cutting-edge therapy through its novel mechanism as a P2Y2 receptor agonist, stimulating tear and mucin secretion. This addresses the underlying causes of dry eye syndrome, normalizing the tear layer and improving corneal epithelial damage.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
19 hours ago
- Malaysian Reserve
Wild About Sprouts® Celebrates World Food Safety Day with Breakthrough Cold-Grown® Technology That Redefines Safety and Nutrition
SCOTTSDALE, Ariz., June 6, 2025 /PRNewswire/ — In honor of World Food Safety Day June 7, Wild About Sprouts® is shining a spotlight on its revolutionary Cold-Grown® process—an all-natural, patented innovation that has redefined food safety standards in the sprouting industry. With over 25 million containers sold pathogen-free and never part of any recall over its 8+ years, Wild About Sprouts is the only national sprout brand in the U.S., now proudly available in over 7,000 grocery stores across the country. Sprouts are among the most powerful, studied, and nutrient-dense superfoods on the planet. Yet for decades, their potential has been limited by persistent food safety concerns. Wild About Sprouts has solved that problem. Its Cold-Grown® process eliminates the risk of dangerous pathogens without the use of pesticides, herbicides, or chemical intervention, and uses 95% less water than traditional growing systems—making it one of the most sustainable solutions in fresh food today. 'At Wild About Sprouts, food safety isn't a feature—it's the foundation,' said Barry Didato, CEO of Rä Foods, parent company of Wild About Sprouts. 'Our patented Cold-Grown® method is changing the way America eats—combining breakthrough safety with unmatched nutrition, delivering sprouts that contain up to 100 times more antioxidants, vitamins, and minerals than fully grown vegetables. Backed by over 2,000 studies, sprouts—especially broccoli sprouts—are rich in sulforaphane, a proven compound that supports the body's natural detox pathways, helps fight cancer, reduces inflammation, and shows promise in managing conditions like autism, diabetes, and neurodegenerative disease.' Observed every year on June 7, World Food Safety Day highlights the importance of safe, accessible food for all. Wild About Sprouts is proud to lead this charge—proving that innovation can make clean, nutrient-packed, fresh foods not just possible, but scalable. 'Wild About Sprouts has not only innovated with its Cold-Grown® technology—they've demonstrated an uncompromising commitment to public health,' said Dr. Darin Detwiler, Food Safety Advocate, Professor and Author of Food Safety: Past, Present, and Predictions. 'In an era when consumers demand both transparency and accountability, this company offers a clear model of how science and responsibility can align to create safer, more sustainable food systems. As we recognize World Food Safety Day, this kind of leadership is precisely what our food system needs to move from reaction to prevention.' Whether tossed in a salad, layered on a sandwich, or blended into smoothies, Wild About Sprouts products offer an easy and delicious way to boost everyday nutrition—safely. For more information, visit or follow us on Instagram at @wild_about_sprouts. Wild About Sprouts is available at major retailers including Kroger, Walmart, Whole Foods Market, Sprouts Farmers Market, Albertsons, and many more. About Wild About Sprouts®Founded in 2016 and based in Scottsdale, Arizona, Wild About Sprouts is transforming the sprout industry with its science-backed, Cold-Grown® technology. As part of Rä Foods, a family office dedicated to better-for-you innovations, Wild About Sprouts is on a mission to deliver safe, delicious, nutrient-dense foods that Make America Healthy Again—one sprout at a time.
BusinessToday
2 days ago
- BusinessToday
No Wires, No Limits: A Bold Leap in Cardiac Tech
Institut Jantung Negara (IJN) has made history with a medical first for Southeast Asia. The team successfully implanted the Abbott AVEIR™ DR, the world's first dual-chamber leadless pacemaker. Approved by the US Food and Drug Administration (FDA) in 2023, this device is a game-changer for individuals with heart rhythm disorders. 'This groundbreaking dual-chamber leadless pacemaker will revolutionise care for our patients and significantly expand the number of people we can help,' said Dr Azlan, Senior Consultant Cardiologist and Clinical Director of Interventional Electrophysiology and Implantable Devices at IJN. 'By eliminating traditional wires (leads) and surgical pockets, the system reduces common complications such as infections, lead dislodgement, and vessel blockage.' Designed for individuals with bradycardia (a slower-than-normal heart rate), AVEIR™ DR represents a significant leap in cardiac pacing. Unlike traditional pacemakers that rely on wires and are implanted under the skin, this system uses two tiny devices (each about one-tenth the size of a conventional pacemaker) implanted directly into the heart's right atrium and ventricle. At the core of this advancement is Abbott's proprietary i2i™ (implant-to-implant) communication technology. This system uses high-frequency pulses conducted through the body's blood flow to synchronise the two pacemakers in real-time. It not only provides beat-to-beat coordination but also conserves battery life far more efficiently than Bluetooth® or radio frequency-based systems. 'This technology opens up new possibilities for patients with abnormal heart rhythms,' added Dr Azlan. 'It also allows real-time pacing analysis during implantation, enabling precise positioning and reducing procedural risks.' At IJN, innovation is not just about adopting the latest medical devices—it's about improving patient outcomes. The successful use of the AVEIR™ DR system is a significant step forward for heart care in the region and further cements IJN's standing as a leader in cardiovascular medicine. Cardiovascular disease continues to pose a serious challenge in Malaysia and across Southeast Asia. IJN's Chief Executive Officer, Prof. Datuk Sri Dr Mohamed Ezani Md Taib, emphasised the importance of early diagnosis, public awareness, and the integration of advanced medical solutions to achieve better patient outcomes. Addressing media questions during a press conference, Dr Azlan addressed questions from the media about the long-term outcomes and potential limitations of the device. He noted that, based on over a decade of experience, the complication rate for leadless pacemakers remains very low—less than 1% in the short term and only slightly higher over the long term. The process of replacing the device when the battery is depleted is also simpler and safer, as there are no leads to remove. As stated, the device is specifically intended for patients with confirmed slow or irregular heart rhythms, typically diagnosed through ECG or other monitoring tools. While pacemakers are not suitable for all heart rhythm disorders, IJN's team is committed to training doctors from across Malaysia and the region to expand access to this life-changing technology. Plans are also underway to collaborate with manufacturers on future innovations tailored to specific patient needs. As with any new medical technology, cost remains a consideration. IJN is working to structure pricing that makes the device accessible to both public and private patients. The hospital's model of using private-sector revenue to subsidise public care will also help ensure broader access as the technology becomes more widely adopted. As the world's first and only dual-chamber leadless pacemaker, the AVEIR™ DR represents a significant advancement in minimally invasive heart care. Its wire-free design reduces risks, enables quicker recovery, and allows for future upgrades—reflecting Abbott's vision to empower patients to live fuller, healthier lives. Related
Barnama
2 days ago
- Barnama
Arctic Wolf Expands into Singapore to Meet Rising Demand for AI-Powered Security Operations
EDEN PRAIRIE, Minn., June 5 (Bernama) -- Arctic Wolf®, a global leader in security operations, today announced its official launch in Singapore, marking the latest milestone in its ongoing expansion across the Asia-Pacific region. Trusted by more than 10,000 organisations worldwide, Arctic Wolf is transforming how businesses manage cybersecurity by delivering scalable, outcome-driven solutions through its Aurora Platform and Concierge Delivery Model. With today's launch, organisations in Singapore can now access the company's full suite of capabilities including Aurora Endpoint Security, Managed Detection and Response, Managed Risk, Managed Security Awareness, and Incident Response. 'As organisations struggle with the challenges of the modern threat landscape, we continue to see strong customer demand across the globe for the Arctic Wolf Aurora Platform and the positive cybersecurity outcomes it delivers,' said Nick Schneider, president and CEO, Arctic Wolf. 'We are excited to bring our portfolio of Security Operations solutions to the business and channel communities of Singapore and look forward to working with them to help end cyber risk.'
